Substitute for form 1449A-B/PTO	C	omplete if Known	Dan
	Application Number	09/502,283	LEFTER
INFORMATION DISCLOSURE	Filing Date	F bruary 11, 2000	T T T
ENENT BY APPLICANT	First Named Inventor	Sun Ai Raillard	Alif & A more
& /	Group Art Unit	Unassign d	- 200 14 200y
6	Examiner Name	Unassigned	The State of the
9 mm (use as many sheets as necessary)	Attorney Docket Number	02-029510US	1600/201

	<del>-                                    </del>		U.	S. PATENT DOCUMENT	S	
PADEMAN Initials	Cite No.	U.S. Patent Docum Number		Name of Patentee or Applicant of Cited Document		Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
170	AA	5,512,463		Stemmer	04-30-1996	
T	AB	5,514,588		Varadaraj	05-07-1996	
	AC	5,605,793		Stemmer	02-25-1997	
	AD	5,763,239		Short et al.	06-09-1998	
	AE	5,789,228		Lam et al.	08-04-1998	
	AF	5,811,238		Stemmer et al.	09-22-1998	
	AG	5,814,473		Warren et al.	09-29-1998	
	АН	5,824,469		Horwitz et al.	10-20-1998	
	Al	5,830,696		Short	11-03-1998	
	AJ	5,830,721		Stemmer et al.	11-03-1998	
	AK	5,834,252		Stemmer et al.	11-10-1998	
	AL	5,837,458		Minushull et al.	11-17-1998	
	AM	5,866,363		Pieczenik	02-02-1999	
	AN	5,876,997		Kretz	03-02-1999	
	AO	5,925,749		Mathur, et al.	07-20-1999	
	AP	5,928,905		Stemmer, et al.	07-27-1999	
	AQ	5,939,250		Short, Jay M.	08-17-1999	
	AR	5,939,300		Robertson, et al.	08-17-1999	
	AS	5,942,430		Robertson, et al.	08-24-1999	
	AT	5,948,666		Callen, et al.	09-07-1999	
	AU	5,958,672		Short, Jay M.	09-28-1999	
	AV	5,958,751		Murphy, et al.	09-28-1999	
	AW	5,962,258		Mathur, et al.	10-05-1999	
	AX	5,962,283		Warren et al.	10-05-1999	
	AY	5,965,408		Short, Jay M.	10-12-1999	
	AZ	5,985,646		Murphy, et al.	11-16-1999	
Th	ВА	6,001,574		Short et al.	12-14-1999	
Examin Signatu		Thomas	Ana	end C	ate onsidered	9/17/02

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO	C	omplete if Known	
	Application Number	09/502,283	
INFORMATION DISCLOSURE	Filing Date	F bruary 11, 2000	
STATEMENT BY APPLICANT	First Named Inventor	Sun Ai Raillard	
	Group Art Unit	Unassign d	
	Examiner Name	Unassigned	
(use as many sheets as necessary)	Attorney Docket Number	02-029510US	

		<i>N</i>				
ı Ma	A Soon	GBB BBB	6,004,788	Short	12-21-1999	
ys.	11/1/	E E E	6,030,779	Short	02-29-2000	
	MADERIA MA	ØD	6,054,267	Short	0 4-25-2000	
さ/	RADERIA			•		,

	т —		Foreign Patent Dag		N PATENT DOCUMEN		Bagos Columns Lines	_
Examiner Initials	Cite No.	Office	Foreign Patent Docume  Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	1
TA	BE	wo	97/07205		Novo Nordisk A/S	02-27-1997		
1	BF	wo	97/20078		Affymax Technologies	06-05-1997		
	BG	wo	97/25410		Novo Nordisk A/S	07-17-1997		
	ВН	wo	97/35957		Maxygen, Inc.	10-02-1997		
	ВІ	wo	97/35966		Maxygen, Inc.	10-02-1997		
	BJ	wo	97/44361		Recombinant Biocatalysis Inc.	11-27-1997		
	ВК	wo	97/48416		Recombinant Biocatalysis, Inc.	12-24-1997		
	BL	wo	97/48717		Recombinant Biocatalysis Inc	12-24-1997		
	ВМ	wo	97/48794		Recombinant Biocatalysis Inc	12-24-1997		
	BN	wo	98/00526		Recombinant Biocatalysis Inc	01-08-1998		
	во	wo	98/01581		Recombinant Biocatalysis Inc	01-15-1998		
	BP	wo	98/13485		Maxygen, Inc.	04-02-1998		
	BQ	wo	98/13487		Maxygen, Inc.	04-02-1998		
	BR	wo	98/24799		Diversa Corp.	06-11-1998		$\prod$
	BS	wo	98/27230		Maxygen, Inc.	06-25-1998		
	вт	wo	98/28416		Novo Nordisk A/S	07-02-1998		
	BU	wo	98/31837		Maxygen, Inc.	07-23-1998		
TA	BV	wo	98/36080		Maxygen, Inc.	08-20-1998		

Examiner		Date	1-1
Signature	Muss Ancend	Considered	9/17/52
Oignature		Considered	1/6 - 1

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

bstitute for form 1449A-B/PTO	C	omplete if Known	
	Application Number	09/502,283	
NFORMATION DISCLOSURE	Filing Date	F bruary 11, 2000	
STATEMENT BY APPLICANT	First Named Inventor	Sun Ai Raillard	
	Group Art Unit	Unassigned	
	Examiner Name	Unassigned	
(use as many sheets as necessary)	Attorney Docket Number	02-029510US	

01							
	TA	<b>B</b> X	wo	98/41622	Novo Nordisk A/S	09-24-1998	
0 3	2000		wo	98/41623	Novo Nordisk A/S	09-24-1998	
			wo	98/41653	Novo Nordisk A/S	09-24-1998	
RADE	ARIL	BZ	wo	98/42832	California Institute of Technology	10-01-1998	
		CA	wo	98/48034	Diversa Corp.	10-29-1998	
		СВ	W	98/58085	Diversa Corp.	12-23-1998	
		CC	W	99/07837	Diversa Corp.	02-19-1999	
		CD	wo	99/08539	Diversa Corp.	02-25-1999	
		.CE	wo	99/10472	Diversa Corp.	03-04-1999	
		CF	WO	99/10539	Diversa Corp.	03-04-1999	
		CG	wo	99/19518	Diversa Corp.	04-22-1999	
		СН	EP	0911396A2	Maxygen, Inc.	04-28-1999	
		CI	WO	99/21979	Maxygen, Inc.	05-06-1999	
		ე	EP	0911396A3	Maxygen, Inc.	05-06-1999	
		СК	wo	99/23107	Maxygen, Inc.	05-14-1999	
		CL	WO	99/23236	Diversa Corp.	05-14-1999	
		СМ	EP	0934999A1	Maxygen, Inc.	08-11-1999	
		CN	wo	99/41368	Maxygen, Inc.	08-19-1999	
		СО	wo	99/41369	Maxygen, Inc.	08-19-1999	
		СР	wo	99/41383	Maxygen, Inc.	08-19-1999	
		CQ	wo	99/41402	Maxygen, Inc.	08-19-1999	
		CR	wo	99/45154	Diversa Corp.	09-10-1999	
	ار ج	CS	wo	99/57128	Maxygen, Inc.	11-11-1999	
10	T	СТ	WO	99/65927	Maxygen, Inc,	12-23-1999	

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т					

			· ·	
Examiner			Date	
Signature	/lans	meny!	Considered	9/17/22
Signature		<del></del>	Ourisidered	11111

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.